Document Detail


Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy.
MedLine Citation:
PMID:  17495447     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We previously reported that a combined therapy with heparin/warfarin and renin-angiotensin system (RAS) inhibitors dramatically reduces proteinuria for prolonged periods in advanced IgA nephropathy (IgAN). In the present study, we prospectively analyzed whether the combined therapy can inhibit the progressive decline in renal function of patients with progressive IgAN. Patients who had a marked linearity of decline in loss of glomerular filtration rate (GFR), assessed by reciprocal serum creatinine plots vs. time for more than one year, were recruited in this study if they were histologically diagnosed as IgAN at this point of declining renal function. Twelve patients were eligible for trial entry; reciprocal serum creatinine plot suggested end-stage renal failure within 5 years. All patients were treated with continuous intravenous infusion of heparin for 8 weeks, followed by oral administration of warfarin, ACE inhibitors and/or angiotensin II receptor blockers and dypiridamole. Eight patients were further given corticosteroid for 2 years because of the presence of acute glomerular lesions such as cellular crescent or angionecrosis. All patients were followed-up for at least 12 months, and the mean follow-up period was 34 +/- 20 (range 12-79) months. After the combined therapy, urinary protein excretion was significantly reduced from 2.4 +/- 1.5 g/day at baseline to 0.7 +/- 0.5 g/day at final observation, while the mean serum creatinine was not significantly different. Of note, the mean slope of 1/serum creatinine significantly increased from -0.009 to +0.0002 dl/mg/week (p < 0.05). Moreover, histological analysis of a repeat kidney biopsy which was performed in 5 patients at 2 years after the institution of the combined therapy revealed that the percentage of cellular/fibrocellular crescent and the degree of mesangial matrix expansion were significantly attenuated (19-->0.1% and 1.6-->0.6 score, respectively) while the percentage of global sclerosis and tubulointerstitial lesion did not increase. These results indicate that our combined therapy with heparin/warfarin and RAS inhibitors can inhibit the progressive decline in renal function Combined Heparin/Warfarin and RAS Inhibitors in Progressive IgAN 115 of patients with progressive IgAN through its marked antiproteinuric and anti-inflammatory effects.
Authors:
Takeo Ishii; Tetsuya Kawamura; Nobuo Tsuboi; Makoto Ogura; Yasunori Utsunomiya; Tatsuo Hosoya
Related Documents :
24337797 - Feasibility and safety of performing outpatient unicompartmental knee arthroplasty.
23183687 - Does a history of postoperative ileus predispose to recurrent ileus after multistage il...
23350877 - Prevention of periprocedural ischemic stroke and management of hemorrhagic complication...
23343667 - Bifurcated coronary stents for infrapopliteal angioplasty in critical limb ischemia.
21786257 - Total hip arthroplasty after excision arthroplasty: indications and limits.
12510547 - Magnetic resonance phase contrast velocity measurement for non-invasive follow up after...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Contributions to nephrology     Volume:  157     ISSN:  0302-5144     ISO Abbreviation:  Contrib Nephrol     Publication Date:  2007  
Date Detail:
Created Date:  2007-05-14     Completed Date:  2007-07-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513582     Medline TA:  Contrib Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  114-9     Citation Subset:  IM    
Affiliation:
Division of Kidney and Hypertension, Department of Medicine, Jikei University School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
Anticoagulants / administration & dosage*
Disease Progression
Drug Therapy, Combination
Female
Glomerulonephritis, IGA / drug therapy*
Heparin / administration & dosage*
Humans
Male
Middle Aged
Prospective Studies
Renin-Angiotensin System / drug effects
Treatment Outcome
Warfarin / administration & dosage
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticoagulants; 81-81-2/Warfarin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sequential immunosuppressive therapy in progressive IgA nephropathy.
Next Document:  Downregulation of the beta1,3- galactosyltransferase gene in tonsillar B lymphocytes and aberrant le...